Background :
@EN There are increased incidence of peripheral vascular diseases in diabetic patients, and may be due to increased fibrinogen, decreased fibrinolytic activity, and increased platelet aggregation. Cilostazol is an antiplatelet agent via
inhibiting
cAMP
dependent phosphodiesterase activity.
@ES Methods:
@EN The clinical safety, efficacy of a cilostazol in non-insulin dependent diabetic patients with peripheral vascular disease (n-=30) accompanied by ischemic symptom such as foot ulcer, resting pain, cold sensation, numbness and claudication in
Yonsei
and Chonnam University Hospitals were evaluated b administering the drug orally in does of 200㎎ for consecutive 8 weeks in a open trial manner. The data analysis was done by student's paired t-test and Chi-square test.
@ES Results:
@EN 1) The score of resting pain, numbness, cold sensation, claudicatio, granuloma were significantly decreased after cilostazol treatment for 8 weeks (p<0.01).
2) The ankle pressure index was significantly increased after cilostazol treatment for 8 weeks.
3) The headache, the most common side effect, was noted in 7 cases (23.3%) of total 30 cases.
4) The assessment of overall improvement of the disease made by the attending physician based onthe improvement of resting pain, cold sensation, claudication and numbness indicated that the percent improvement based on the combined assessments
of
"markedly improved", "improved" and "slightly improved" amounted to 83.3%.
5) The assessment of overall safety of the drug evaluated by the attending physician based on the assessment of "safe" and "almost safe" amounted to 86.7%.
6) The assessment of overall utility of the drug evaluated by the attending physician based on the assessment of "very useful", "useful" and "slightly useful"' amounted to 83.3%.
@ES Conclusion :
@EN It was concluded that cilostazol was useful in the treatment of diabetic patients with peripheral vascular disease accompanied by ischemic symptom such as resting pain, cold sensatin, claudication and numbness in the extremities at an optimal
daily
dose of 200㎎.
|